Pulmonx US Careers

Pulmonx strives to be the cornerstone of interventional pulmonology by focusing on developing life-changing, cost-effective technologies that improve the lives of patients suffering from lung disease worldwide.

Pulmonx is a privately-held commercial stage medical device company focused on developing both diagnostic and therapeutic technologies for Interventional Pulmonology. The Company’s first commercial products address emphysema, a form of COPD and the largest unmet medical need in Pulmonology. Pulmonx has developed the Endobronchial Valve (EBV) Therapy, a non-surgical approach to treating emphysema that uses the Chartis Pulmonary Assessment System to optimize the placement of a series of unique self-expanding valves. The Zephyr® Endobronchial Valve is designed to reduce the volume of the diseased region of the lung by blocking airflow.

Pulmonx products are commercially available in Europe, Australia, Asia, Latin America and other countries worldwide. The company does not yet market or sell its products in the United States.

Company Tiimeline


1 Davey C, Zoumot Z, McNulty W, Jordan S, Carr D, Rubens M, Hansell D, Polkey M, Shah P, Hopkinson N. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fi ssures (BeLieVer-HIFi). Eur Respir J 2014; 44: Suppl. 58, A1773.
2 Pietzsch JB, Garner A, Herth FJF. Cost-Effectiveness of Endobronchial Valve Therapy for Severe Emphysema: A Model-Based Projection Based on the VENT Study. Respiration (DOI: 10.1159/000368088). Published online: September 30.
3 Herth FJF, Eberhardt R, Gompelmann D, Ficker JH, Wagner M, Ek L, Schmidt B and Slebos D-J. Radiological and Clinical Outcomes of Using Chartis to Plan Endobronchial Valve Treatment. Eur Respir J 2013; 41(2): 302-308.
4 Herth F, Noppen M, Valipour A, Leroy S, Vergnon J-M, Ficker JH, Egan E, Gasparini S, Agusti C, Homes-Higgin D, Ernst A on behalf of the International VENT Study Group. Efficacy predictors of endoscopic lung volume reduction with Zephyr valves in a European cohort with emphysema. Eur Respir J 2012; 39: 1334-1342.
5 Hopkinson NS, Kemp SV, Toma TP, Hansell DM, Geddes DM, Shah PL, Polkey MI. Atelectasis and survival after bronchoscopic lung volume reduction for COPD. Eur Respir J 2011; 37(6): 1346-51.
6 Sciurba FC, Ernst A, Herth FJF, Strange C, Criner G, Marquette C, et al. A Randomized Study of Endobronchial Valves for Advanced Emphysema. New Eng J Med 2010; 363: 1233-1244 (including supplementary appendix).

CAUTION: The Zephyr Endobronchial Valve is an investigational device in the US, limited by US law to investigational use.